Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
By
marc__1
Hot, fresh, and worth queueing round the block for.
Summary
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic cancers in a clinical trial. Unlike previous CD40 antibodies that showed promise in animal models but failed in humans due to severe toxicity and limited efficacy, this new engineered version activates immune cells more precisely while reducing systemic inflammation, low platelet counts, and liver toxicity. The treatment led to complete remission in some patients with metastatic cancer, representing a significant breakthrough for immunotherapy.
Key quotes
· 3 pulledWhile effective at activating the immune system to kill cancer cells in animal models, the drugs had limited impact on patients in clinical trials and caused dangerously systemic inflammatory responses, low platelet counts, and liver toxicity, among other adverse reactions—even at a low dose.
The researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.
Histology image of a patient whose metastatic cancer went into complete remission after receiving a new immunotherapy treatment
You might also wanna read
Triple-action cancer jab amivantamab shrinks tumors in over a third of patients in international trial
An international trial across 11 countries shows that a triple-action cancer injection called amivantamab can shrink or completely eradicate
theguardian.com·1d ago
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1h ago
International trial shows DNA test could help many breast cancer patients avoid chemotherapy
A new international trial presented at the American Society of Clinical Oncology conference suggests that millions of breast cancer patients
bbc.co.uk·1d ago
Molecular glue approach doubles survival time for aggressive pancreatic cancer patients
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·2h ago